IMV Inc. announced preliminary data from the VITALIZE Phase 2B trial evaluating its lead DPX product, maveropepimut-S, or MVP-S, in combination with pembrolizumab in patients with relapsed, refractory Diffuse Large B Cell Lymphoma, or r/r DLBCL. Key initial findings from the ongoing VITALIZE trial: eight patients with an ECOG1 score of 0-1 have been enrolled in arm 1 of the study. Of these, 6 have so far been evaluable for efficacy; of these six evaluable patients, three patients showed confirmed complete responses, one patient was assessed with stable disease as best response and two patients were assessed with progressive disease as best response and two patients with poor level of baseline functionality failed to stay on study through to the first scan and therefore could not be evaluated. Overall Response Rate will be communicated when the totality of stage one data are available for definitive assessment.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on IMV:
